本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ALX Oncology Holdings

2.45
-0.1500-5.77%
盤後2.44-0.0100-0.41%19:17 EST
成交量:49.82萬
成交額:123.48萬
市值:3.21億
市盈率:-1.22
高:2.60
開:2.59
低:2.38
收:2.60
52周最高:2.66
52周最低:0.4040
股本:1.31億
流通股本:1.05億
量比:0.48
換手率:0.47%
股息:- -
股息率:- -
每股收益(TTM):-2.0149
每股收益(LYR):-2.5846
淨資產收益率:-118.95%
總資產收益率:-50.49%
市淨率:7.17
市盈率(LYR):-0.95

資料載入中...

公司資料

公司名字:
ALX Oncology Holdings
交易所:
NASDAQ
成立時間:
2015
員工人數:
44
公司地址:
323 Allerton Avenue,South San Francisco,California,United States
郵編:
94080
電話:
傳真:
- -
簡介:
ALX Oncology Holdings Inc.於2020年4月1日成立。該公司是一家臨床階段的免疫腫瘤學公司,專註於通過開發阻斷CD47免疫檢查點和連接先天和適應性免疫系統的療法來幫助患者對抗癌症。

董事

名稱
職位
Corey Goodman
Executive Chairman of the Board
Jason Lettmann
Chief Executive Officer and Director
Alan B. Sandler
Director and Chief Medical Officer
Chris H. Takimoto
Independent Director
Rekha Hemrajani
Independent Director
Scott Garland
Independent Director
Daniel Curran
Director

股東

名稱
職位
Jason Lettmann
Chief Executive Officer and Director
Harish Shantharam
Chief Financial Officer
Shelly Pinto
Senior Vice President, Finance and Chief Accounting Officer
Alan B. Sandler
Director and Chief Medical Officer
Corey Goodman
Executive Chairman of the Board